文献速递帕金森病与运动障碍认知障碍与痴呆

家族性帕金森病与路易体痴呆中的LRP10基因变异:一项全基因组连锁与测序研究

LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.
PubMed 文献 · Lancet Neurol · 2018-06-07

该研究分三阶段:对一个意大利常染色体显性帕金森病家系行全基因组连锁分析提名LRP10为致病基因;在国际多中心660例先证者中检出8例携带罕见可能致病LRP10变异(645例腹主动脉瘤对照中1例携带);在葡萄牙、撒丁岛和台湾独立系列中3例帕金森病先证者检出其中2种变异而对照均无。尸检3例携带不同LRP10变异者均见严重路易体病理,体外研究提示LRP10功能丧失为共同致病机制。

要点

  • 全基因组连锁分析将意大利常染色体显性帕金森病家系定位于14号染色体并提名LRP10为致病基因。
  • 国际多中心660例先证者中8例携带罕见可能致病LRP10变异,645例腹主动脉瘤对照中仅1例携带。
  • 独立系列中3例帕金森病先证者检出其中2种变异而对照均无;3例携带者尸检均见严重路易体病理。

核心结论

  • 研究结果提示LRP10基因缺陷参与遗传性α-突触核蛋白病的发生。
  • 作者认为未来阐明LRP10蛋白功能及通路可能为机制、生物标志物和治疗靶点提供新见解。

研究设计与样本

  • 研究分三阶段:首先对意大利常染色体显性帕金森病家系行全基因组连锁分析。
  • 其次在国际多中心系列660例临床或病理诊断的帕金森病、帕金森病痴呆或路易体痴呆无关先证者中测序候选基因,对照为未行神经系统检查的腹主动脉瘤个体645例。
  • 第三阶段从葡萄牙、撒丁岛和台湾中心纳入独立系列临床诊断帕金森病患者及无帕金森病、帕金森病痴呆或路易体痴呆体征或家族史的对照,筛查特定变异。
  • 另对国际多中心系列中3例携带疾病相关变异的患者行mRNA和脑病理研究,并在体外模型(包括诱导多能干细胞样细胞来源神经元)中行功能蛋白研究。
  • 分子研究于2008年1月1日至2017年12月31日进行。

主要发现

  • 初始意大利家系10例受累者(平均发病年龄59.8岁[SD 8.7])显示帕金森病与14号染色体显著连锁,提名LRP10为致病基因。
  • 国际系列660例先证者中检出8例携带不同罕见可能致病LRP10变异(4例帕金森病、2例帕金森病痴呆、2例路易体痴呆);645例腹主动脉瘤对照中1例携带。
  • 独立系列中上述8种变异中的2种在3例额外帕金森病先证者中检出(撒丁岛2例、台湾1例),对照中均未检出。
  • 国际与独立队列中11例携带LRP10变异的先证者中10例有阳性家族史,7个家系中10例受累亲属有DNA可用,其中9例携带LRP10变异,提供独立但有限的共分离证据。
  • 3例携带不同LRP10变异患者尸检显示严重路易体病理;9种变异中3种严重影响LRP10表达和mRNA稳定性(1424+5delG、1424+5G→A、Ala212Serfs*17,经cDNA分析),4种影响蛋白稳定性(Tyr307Asn、Gly603Arg、Arg235Cys、Pro699Ser,经放线菌酮追踪实验),2种影响蛋白定位(Asn517del、Arg533Leu,经免疫细胞化学),提示LRP10功能丧失为共同致病机制。

关键数值与推荐

  • 初始家系10例受累意大利个体平均发病年龄59.8岁(SD 8.7)。
  • 国际系列660例先证者中8例携带罕见可能致病LRP10变异;645例腹主动脉瘤对照中1例携带。
  • 11例携带LRP10变异的先证者中10例有阳性家族史;7个家系中10例受累亲属有DNA,其中9例携带变异。
  • 9种变异功能后果:3种影响表达和mRNA稳定性(1424+5delG、1424+5G→A、Ala212Serfs*17),4种影响蛋白稳定性(Tyr307Asn、Gly603Arg、Arg235Cys、Pro699Ser),2种影响蛋白定位(Asn517del、Arg533Leu)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 共分离证据为独立但有限(independent-albeit limited-evidence)。
  • 作者认为未来需阐明LRP10蛋白功能及通路(Future elucidation of the function of the LRP10 protein and pathways could offer novel insights)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies do not carry mutations in known disease-causing genes. The aim of this study was to identify a novel gene implicated in the development of these disorders. METHODS: Our study was done in three stages. First, we did genome-wide linkage analysis of an Italian family with dominantly inherited Parkinson's disease to identify the disease locus. Second, we sequenced the candidate gene in an international multicentre series of unrelated probands who were diagnosed either clinically or pathologically with Parkinson's disease, Parkinson's disease dementia, or dementia with Lewy bodies. As a control, we used gene sequencing data from individuals with abdominal aortic aneurysms (who were not examined neurologically). Third, we enrolled an independent series of patients diagnosed clinically with Parkinson's disease and controls with no signs or family history of Parkinson's disease, Parkinson's disease dementia, or dementia with Lewy bodies from centres in Portugal, Sardinia, and Taiwan, and screened them for specific variants. We also did mRNA and brain pathology studies in three patients from the international multicentre series carrying disease-associated variants, and we did functional protein studies in in-vitro models, including neurons from induced pluripotent stem-like cells. FINDINGS: Molecular studies were done between Jan 1, 2008, and Dec 31, 2017. In the initial kindred of ten affected Italian individuals (mean age of disease onset 59·8 years [SD 8·7]), we detected significant linkage of Parkinson's disease to chromosome 14 and nominated LRP10 as the disease-causing gene. Among the international series of 660 probands, we identified eight individuals (four with Parkinson's disease, two with Parkinson's disease dementia, and two with dementia with Lewy bodies) who carried different, rare, potentially pathogenic LRP10 variants; one carrier was found among 645 controls with abdominal aortic aneurysms. In the independent series, two of these eight variants were detected in three additional Parkinson's disease probands (two from Sardinia and one from Taiwan) but in none of the controls. Of the 11 probands from the international and independent cohorts with LRP10 variants, ten had a positive family history of disease and DNA was available from ten affected relatives (in seven of these families). The LRP10 variants were present in nine of these ten relatives, providing independent-albeit limited-evidence of co-segregation with disease. Post-mortem studies in three patients carrying distinct LRP10 variants showed severe Lewy body pathology. Of nine variants identified in total (one in the initial family and eight in stage 2), three severely affected LRP10 expression and mRNA stability (1424+5delG, 1424+5G→A, and Ala212Serfs*17, shown by cDNA analysis), four affected protein stability (Tyr307Asn, Gly603Arg, Arg235Cys, and Pro699Ser, shown by cycloheximide-chase experiments), and two affected protein localisation (Asn517del and Arg533Leu; shown by immunocytochemistry), pointing to loss of LRP10 function as a common pathogenic mechanism. INTERPRETATION: Our findings implicate LRP10 gene defects in the development of inherited forms of α-synucleinopathies. Future elucidation of the function of the LRP10 protein and pathways could offer novel insights into mechanisms, biomarkers, and therapeutic targets. FUNDING: Stichting ParkinsonFonds, Dorpmans-Wigmans Stichting, Erasmus Medical Center, ZonMw-Memorabel programme, EU Joint Programme Neurodegenerative Disease Research (JPND), Parkinson's UK, Avtal om Läkarutbildning och Forskning (ALF) and Parkinsonfonden (Sweden), Lijf and Leven foundation, and cross-border grant of Alzheimer Netherlands-Ligue Européene Contre la Maladie d'Alzheimer (LECMA).

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Quadri M, Mandemakers W, Grochowska MM, et al. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurol. 2018. PMID: 29887161. doi:10.1016/S1474-4422(18)30179-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。